Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

B-SMART partner VIB announces the publication of a new paper in the journal EMBO Molecular Medicine. In it,  Prof. Roosmarijn Vandenbroucke and her research team report that tumor necrosis factor (TNF), via activation of its receptor TNFR1, is the main inflammatory upstream mediator of the with Alzheimer’s disease (AD) associated changes at the choroid plexus and that targeting TNF/TNFR1 signaling has therapeutic potential. An important limitation of the current study is the fact that the anti-TNFR1 Nanobody® was directly injected into the brain, thereby circumventing one of the major challenges of successful therapy for central nervous system (CNS) disorders: drug delivery across the tight brain barriers. Prof. Vandenbroucke hopes that the work in B-SMART will address this limitation.

More on the article can be found here.

The article can be found here.

Tweet this article